Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bolandiol is a synthetic anabolic-androgenic steroid (AAS) that was never marketed in its base form, though its dipropionate ester derivative has been marketed. It is unique among AASs for possessing not only androgenic but also estrogenic and progestogenic activity. Bolandiol acts as an agonist at the androgen receptor (AR), estrogen receptor alpha (ERα), estrogen receptor beta (ERβ), progesterone receptor A (PR-A), and progesterone receptor B (PR-B), but with lower potency compared to natural ligands such as testosterone or estradiol. In animal studies, it increases lean body mass and bone mineral density while exhibiting tissue selectivity—stimulating muscle growth comparably to testosterone but with minimal effect on sex accessory glands like the prostate. This profile suggests potential use as a "prostate-sparing" androgen or male contraceptive. Bolandiol suppresses gonadotropins and endogenous testosterone production, is considered a metabolic precursor to nandrolone, and has been used illicitly as a performance-enhancing supplement by athletes; it is banned by the World Anti-Doping Agency[1][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bolandiol.